Want to see AZTA full AI Analyst Report?
AZTA Stock Chart & Stats
$28.93
-$0.65(-2.25%)
At close: 4:00 PM EDT
$28.93
-$0.65(-2.25%)
Day’s Range― - ―
52-Week Range$15.93 - $41.73
Previous Close$28.28
Volume692.82K
Average Volume (3M)965.29K
Market Cap
$1.64B
Enterprise Value$881.45
Total Cash (Recent Filing)$325.80M
Total Debt (Recent Filing)$53.97M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 17, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume770,217
30 Day Avg. Volume965,289
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside20.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.39
Revenue Forecast (FY)$600.44M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue BaseA substantial recurring-revenue base from biorepositories, consumables and related services improves revenue visibility and customer retention. Continued growth in these areas can make results more resilient than a model relying mainly on one-time instrument sales.
Conservative Balance SheetVery low leverage and a sizable equity cushion reduce refinancing and solvency risk. This financial flexibility gives Azenta more capacity to fund product development, manage operational issues and pursue strategic opportunities through changing demand conditions.
Multiomics GrowthGrowth in NGS and gene synthesis, alongside meaningful gross-margin improvement, supports Multiomics as a potentially stronger long-term growth engine. Higher volumes could improve operating leverage and help offset weakness in mature sequencing activities.
Bears Say
Persistent UnprofitabilityAzenta has not yet demonstrated durable earnings conversion despite revenue stabilization and a mid-40% gross margin. Continued operating losses constrain internally funded growth, weaken returns on capital and increase dependence on successful execution of its improvement plans.
Margin Pressure And RemediationLower margins in Sample Management Solutions, quality remediation and fixed-cost absorption indicate execution and cost-structure challenges. These issues can persist beyond one quarter, delaying operating leverage and limiting the benefit of revenue growth.
Sanger Sequencing DeclineThe decline in Sanger sequencing reflects a structural technology transition rather than a temporary demand fluctuation. Ongoing mix pressure may weigh on Multiomics profitability and require sustained investment in faster-growing genomic services.
Azenta News
AZTA FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest stock price was $15.93 and its highest was $41.73 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.64B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 17, 2026 which is in 85 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 04, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.046.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.16.
How many shares outstanding does Azenta have?
Azenta has 43,808,390 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.16 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went up 5.609%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in AZTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (20.98% Upside)
$35.00 (20.98% Upside)
Blogger Sentiment
Bullish
AZTA Sentiment 75%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 402.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $163.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
AZTA Company Deck
AZTA Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.View all AZTA earnings summariesAZTA Stock 12 Month Forecast
Average Price Target
$35.00
▲(20.98% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
39.34% Mutual Funds
8.85% Other Institutional Investors
8.54% Public Companies and
Individual Investors